Instituto de Cancer e Transplante de Curitiba ICTR ( Site 2306)

Curitiba, Paraná 80510-130

0 studies enrolling now · 1 studies all time

What they study most

Metastatic Hormone-Sensitive Prostate Cancer

Studies at this site

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) — Completed